MWNA
ITCI

Marshall Wace North America’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Marshall Wace North America’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-480,301
Closed -$15.3M – 1829
2020
Q4 		$15.3M Hold
480,301
– – 0.07% 298
2020
Q3 		$12.3M Buy
+480,301
New +$11M 0.08% 251
2017
Q4 		– Sell
-84,358
Closed -$1.35M – 1655
2017
Q3 		$1.35M Buy
+84,358
New +$1.24M 0.01% 888

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Marshall Wace North America's ITCI Position: Q1 2021 in Review

Marshall Wace North America sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2021, closing a stake of 480,301 shares — an estimated $15.3M sold.

Marshall Wace North America first reported a position in ITCI in Q3 2017 and held it in 3 quarters. The position peaked at $15.3M in Q4 2020. 170 funds tracked by Wall St. Rank hold ITCI as of Q1 2021.

  • Marshall Wace North America reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 480,301 Intra-Cellular Therapies Inc. shares in Q1 2021, an estimated $15.3M.
  • Marshall Wace North America first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 3 quarters.
  • Marshall Wace North America's Intra-Cellular Therapies Inc. position peaked at $15.3M in Q4 2020.
  • 170 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.